AR049294A1 - DERIVADOS DE QUINAZOLINA; INHIBIDORES DE LA TIROSINA QUINASA DEL RECEPTOR ERBB2; COMPOSICIONES FARMACÉUTICAS QUE LOS CONTIENEN; MÉTODOS PARA SU PREPARACIoN Y SU USO COMO MEDICAMENTO PARA EL TRATAMIENTO O PREVENCIoN DE TUMORES SoLIDOS. - Google Patents
DERIVADOS DE QUINAZOLINA; INHIBIDORES DE LA TIROSINA QUINASA DEL RECEPTOR ERBB2; COMPOSICIONES FARMACÉUTICAS QUE LOS CONTIENEN; MÉTODOS PARA SU PREPARACIoN Y SU USO COMO MEDICAMENTO PARA EL TRATAMIENTO O PREVENCIoN DE TUMORES SoLIDOS.Info
- Publication number
- AR049294A1 AR049294A1 ARP050102306A ARP050102306A AR049294A1 AR 049294 A1 AR049294 A1 AR 049294A1 AR P050102306 A ARP050102306 A AR P050102306A AR P050102306 A ARP050102306 A AR P050102306A AR 049294 A1 AR049294 A1 AR 049294A1
- Authority
- AR
- Argentina
- Prior art keywords
- 6alkyl
- group
- formula
- alkyl
- necessary
- Prior art date
Links
- 238000000034 method Methods 0.000 title abstract 9
- JWVCLYRUEFBMGU-UHFFFAOYSA-N quinazoline Chemical class N1=CN=CC2=CC=CC=C21 JWVCLYRUEFBMGU-UHFFFAOYSA-N 0.000 title abstract 7
- 206010028980 Neoplasm Diseases 0.000 title abstract 2
- 239000003814 drug Substances 0.000 title abstract 2
- 239000008194 pharmaceutical composition Substances 0.000 title abstract 2
- 230000002265 prevention Effects 0.000 title abstract 2
- 101001012157 Homo sapiens Receptor tyrosine-protein kinase erbB-2 Proteins 0.000 title 1
- 102100030086 Receptor tyrosine-protein kinase erbB-2 Human genes 0.000 title 1
- 229940079593 drug Drugs 0.000 title 1
- 229940043355 kinase inhibitor Drugs 0.000 title 1
- 239000003757 phosphotransferase inhibitor Substances 0.000 title 1
- 239000007787 solid Substances 0.000 title 1
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 abstract 16
- 125000000524 functional group Chemical group 0.000 abstract 12
- 229910052757 nitrogen Inorganic materials 0.000 abstract 12
- 125000001424 substituent group Chemical group 0.000 abstract 10
- 229910052736 halogen Inorganic materials 0.000 abstract 7
- 150000002367 halogens Chemical class 0.000 abstract 7
- 125000000623 heterocyclic group Chemical group 0.000 abstract 7
- 229910052739 hydrogen Inorganic materials 0.000 abstract 7
- 239000001257 hydrogen Substances 0.000 abstract 7
- 125000004191 (C1-C6) alkoxy group Chemical group 0.000 abstract 6
- 238000006243 chemical reaction Methods 0.000 abstract 6
- 229910052760 oxygen Inorganic materials 0.000 abstract 6
- 150000003246 quinazolines Chemical class 0.000 abstract 5
- 125000004890 (C1-C6) alkylamino group Chemical group 0.000 abstract 4
- 125000004739 (C1-C6) alkylsulfonyl group Chemical group 0.000 abstract 4
- 125000004397 aminosulfonyl group Chemical group NS(=O)(=O)* 0.000 abstract 4
- 125000001589 carboacyl group Chemical group 0.000 abstract 4
- -1 cyano, nitro, hydroxy, amino, carboxy, carbamoyl Chemical group 0.000 abstract 4
- 125000004356 hydroxy functional group Chemical group O* 0.000 abstract 4
- 125000004178 (C1-C4) alkyl group Chemical group 0.000 abstract 3
- 125000004738 (C1-C6) alkyl sulfinyl group Chemical group 0.000 abstract 3
- 125000006700 (C1-C6) alkylthio group Chemical group 0.000 abstract 3
- 125000006619 (C1-C6) dialkylamino group Chemical group 0.000 abstract 3
- 125000000882 C2-C6 alkenyl group Chemical group 0.000 abstract 3
- 125000003601 C2-C6 alkynyl group Chemical group 0.000 abstract 3
- 125000004423 acyloxy group Chemical group 0.000 abstract 3
- 125000005236 alkanoylamino group Chemical group 0.000 abstract 3
- 150000001412 amines Chemical class 0.000 abstract 3
- 229910002091 carbon monoxide Inorganic materials 0.000 abstract 3
- 125000004435 hydrogen atom Chemical group [H]* 0.000 abstract 3
- 125000004433 nitrogen atom Chemical group N* 0.000 abstract 3
- 229910052717 sulfur Inorganic materials 0.000 abstract 3
- 125000000229 (C1-C4)alkoxy group Chemical group 0.000 abstract 2
- 125000004454 (C1-C6) alkoxycarbonyl group Chemical group 0.000 abstract 2
- 125000004845 (C1-C6) alkylsulfonylamino group Chemical group 0.000 abstract 2
- 125000006272 (C3-C7) cycloalkyl group Chemical group 0.000 abstract 2
- 125000004648 C2-C8 alkenyl group Chemical group 0.000 abstract 2
- 125000004649 C2-C8 alkynyl group Chemical group 0.000 abstract 2
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 abstract 2
- 125000003282 alkyl amino group Chemical group 0.000 abstract 2
- 125000000217 alkyl group Chemical group 0.000 abstract 2
- 150000001408 amides Chemical class 0.000 abstract 2
- 125000006620 amino-(C1-C6) alkyl group Chemical group 0.000 abstract 2
- 125000003917 carbamoyl group Chemical group [H]N([H])C(*)=O 0.000 abstract 2
- 229910052799 carbon Inorganic materials 0.000 abstract 2
- 150000001875 compounds Chemical class 0.000 abstract 2
- 125000004093 cyano group Chemical group *C#N 0.000 abstract 2
- 150000002431 hydrogen Chemical class 0.000 abstract 2
- 150000003839 salts Chemical class 0.000 abstract 2
- PXQLVRUNWNTZOS-UHFFFAOYSA-N sulfanyl Chemical class [SH] PXQLVRUNWNTZOS-UHFFFAOYSA-N 0.000 abstract 2
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 abstract 2
- NAWXUBYGYWOOIX-SFHVURJKSA-N (2s)-2-[[4-[2-(2,4-diaminoquinazolin-6-yl)ethyl]benzoyl]amino]-4-methylidenepentanedioic acid Chemical compound C1=CC2=NC(N)=NC(N)=C2C=C1CCC1=CC=C(C(=O)N[C@@H](CC(=C)C(O)=O)C(O)=O)C=C1 NAWXUBYGYWOOIX-SFHVURJKSA-N 0.000 abstract 1
- 125000004916 (C1-C6) alkylcarbonyl group Chemical group 0.000 abstract 1
- 125000006656 (C2-C4) alkenyl group Chemical group 0.000 abstract 1
- 125000006650 (C2-C4) alkynyl group Chemical group 0.000 abstract 1
- 125000000954 2-hydroxyethyl group Chemical group [H]C([*])([H])C([H])([H])O[H] 0.000 abstract 1
- 125000001963 4 membered heterocyclic group Chemical group 0.000 abstract 1
- 125000002373 5 membered heterocyclic group Chemical group 0.000 abstract 1
- 125000004070 6 membered heterocyclic group Chemical group 0.000 abstract 1
- 125000003341 7 membered heterocyclic group Chemical group 0.000 abstract 1
- 125000003320 C2-C6 alkenyloxy group Chemical group 0.000 abstract 1
- 102000001301 EGF receptor Human genes 0.000 abstract 1
- 108060006698 EGF receptor Proteins 0.000 abstract 1
- 101001043818 Mus musculus Interleukin-31 receptor subunit alpha Proteins 0.000 abstract 1
- 102000004022 Protein-Tyrosine Kinases Human genes 0.000 abstract 1
- 108090000412 Protein-Tyrosine Kinases Proteins 0.000 abstract 1
- 230000003213 activating effect Effects 0.000 abstract 1
- 125000000304 alkynyl group Chemical group 0.000 abstract 1
- 125000005133 alkynyloxy group Chemical group 0.000 abstract 1
- 230000001028 anti-proliverative effect Effects 0.000 abstract 1
- 125000003118 aryl group Chemical group 0.000 abstract 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical group [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 abstract 1
- 125000004432 carbon atom Chemical group C* 0.000 abstract 1
- 239000003795 chemical substances by application Substances 0.000 abstract 1
- 230000008878 coupling Effects 0.000 abstract 1
- 239000007822 coupling agent Substances 0.000 abstract 1
- 238000010168 coupling process Methods 0.000 abstract 1
- 238000005859 coupling reaction Methods 0.000 abstract 1
- 125000000392 cycloalkenyl group Chemical group 0.000 abstract 1
- 125000002485 formyl group Chemical group [H]C(*)=O 0.000 abstract 1
- 125000001072 heteroaryl group Chemical group 0.000 abstract 1
- 125000005842 heteroatom Chemical group 0.000 abstract 1
- 230000005764 inhibitory process Effects 0.000 abstract 1
- 238000004519 manufacturing process Methods 0.000 abstract 1
- 239000001301 oxygen Substances 0.000 abstract 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 abstract 1
- 125000006239 protecting group Chemical group 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
- C07D239/72—Quinazolines; Hydrogenated quinazolines
- C07D239/78—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in position 2
- C07D239/84—Nitrogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP04291393 | 2004-06-04 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR049294A1 true AR049294A1 (es) | 2006-07-12 |
Family
ID=34969245
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP050102306A AR049294A1 (es) | 2004-06-04 | 2005-06-06 | DERIVADOS DE QUINAZOLINA; INHIBIDORES DE LA TIROSINA QUINASA DEL RECEPTOR ERBB2; COMPOSICIONES FARMACÉUTICAS QUE LOS CONTIENEN; MÉTODOS PARA SU PREPARACIoN Y SU USO COMO MEDICAMENTO PARA EL TRATAMIENTO O PREVENCIoN DE TUMORES SoLIDOS. |
Country Status (16)
| Country | Link |
|---|---|
| US (1) | US20070232607A1 (cg-RX-API-DMAC7.html) |
| EP (1) | EP1756088A1 (cg-RX-API-DMAC7.html) |
| JP (1) | JP2008501675A (cg-RX-API-DMAC7.html) |
| KR (1) | KR20070038500A (cg-RX-API-DMAC7.html) |
| CN (1) | CN1993349A (cg-RX-API-DMAC7.html) |
| AR (1) | AR049294A1 (cg-RX-API-DMAC7.html) |
| AU (1) | AU2005250224A1 (cg-RX-API-DMAC7.html) |
| BR (1) | BRPI0511741A (cg-RX-API-DMAC7.html) |
| CA (1) | CA2567832A1 (cg-RX-API-DMAC7.html) |
| IL (1) | IL179081A0 (cg-RX-API-DMAC7.html) |
| MX (1) | MXPA06014125A (cg-RX-API-DMAC7.html) |
| NO (1) | NO20066081L (cg-RX-API-DMAC7.html) |
| TW (1) | TW200602328A (cg-RX-API-DMAC7.html) |
| UY (1) | UY28940A1 (cg-RX-API-DMAC7.html) |
| WO (1) | WO2005118572A1 (cg-RX-API-DMAC7.html) |
| ZA (1) | ZA200609427B (cg-RX-API-DMAC7.html) |
Families Citing this family (34)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE60231230D1 (de) * | 2001-11-03 | 2009-04-02 | Astrazeneca Ab | Quinazolin derivate als antitumor-mittel |
| GB0126433D0 (en) * | 2001-11-03 | 2002-01-02 | Astrazeneca Ab | Compounds |
| GB0309009D0 (en) * | 2003-04-22 | 2003-05-28 | Astrazeneca Ab | Quinazoline derivatives |
| GB0309850D0 (en) * | 2003-04-30 | 2003-06-04 | Astrazeneca Ab | Quinazoline derivatives |
| EP1664028A1 (en) * | 2003-09-16 | 2006-06-07 | AstraZeneca AB | Quinazoline derivatives as tyrosine kinase inhibitors |
| GB0321648D0 (en) * | 2003-09-16 | 2003-10-15 | Astrazeneca Ab | Quinazoline derivatives |
| WO2005026156A1 (en) * | 2003-09-16 | 2005-03-24 | Astrazeneca Ab | Quinazoline derivatives |
| BRPI0414489A8 (pt) | 2003-09-16 | 2019-01-15 | Astrazeneca Ab | derivado de quinazolina, composição farmacêutica, uso de um derivado de quinazolina, e, processo para a preparação de um derivado de quinazolina |
| KR20070027487A (ko) * | 2003-09-16 | 2007-03-09 | 아스트라제네카 아베 | 퀴나졸린 유도체 |
| GB0322409D0 (en) * | 2003-09-25 | 2003-10-29 | Astrazeneca Ab | Quinazoline derivatives |
| GB0326459D0 (en) * | 2003-11-13 | 2003-12-17 | Astrazeneca Ab | Quinazoline derivatives |
| WO2005075439A1 (en) * | 2004-02-03 | 2005-08-18 | Astrazeneca Ab | Quinazoline derivatives |
| DE602005026865D1 (de) * | 2004-12-14 | 2011-04-21 | Astrazeneca Ab | Pyrazolopyrimidinverbindungen als antitumormittel |
| GB0504474D0 (en) * | 2005-03-04 | 2005-04-13 | Astrazeneca Ab | Chemical compounds |
| GB0508717D0 (en) * | 2005-04-29 | 2005-06-08 | Astrazeneca Ab | Chemical compounds |
| GB0508715D0 (en) * | 2005-04-29 | 2005-06-08 | Astrazeneca Ab | Chemical compounds |
| ATE488513T1 (de) * | 2005-09-20 | 2010-12-15 | Astrazeneca Ab | 4-(1h-indazol-5-ylamino)chinazolinverbindungen als inhibitoren der erbb-rezeptortyrosinkinase zur behandlung von krebs |
| JP2009508917A (ja) * | 2005-09-20 | 2009-03-05 | アストラゼネカ アクチボラグ | 抗癌剤としてのキナゾリン誘導体 |
| US20100222344A1 (en) * | 2005-12-02 | 2010-09-02 | Astrazeneca Ab | 4-anilino-substituted quinazoline derivatives as tyrosine kinase inhibitors |
| EP1960371B1 (en) * | 2005-12-02 | 2009-09-16 | AstraZeneca AB | Quinazoleine derivatives used as inhibitors of erbb tyrosine kinase |
| ES2654847T3 (es) | 2006-04-19 | 2018-02-15 | Novartis Ag | Compuestos de benzoxazol y benzotiazol sustituidos en 6-O y métodos para inhibir la señalización CSF-1R |
| KR101129868B1 (ko) | 2006-10-04 | 2012-04-12 | 화이자 프로덕츠 인코포레이티드 | 칼슘 수용체 길항제로서의 피리도［4,3-ｄ］피리미딘-4(3Ｈ)-온 유도체 |
| WO2008046085A2 (en) * | 2006-10-12 | 2008-04-17 | Supergen, Inc. | Quinoline derivatives for modulating dna methylation |
| JP5516397B2 (ja) | 2007-04-05 | 2014-06-11 | アムジエン・インコーポレーテツド | オーロラキナーゼ調節物質及び使用方法 |
| US7790746B2 (en) | 2007-10-12 | 2010-09-07 | Supergen, Inc. | Quinoline derivatives for modulating DNA methylation |
| US7939546B2 (en) | 2007-10-12 | 2011-05-10 | Supergen, Inc. | Quinoline derivatives for modulating DNA methylation |
| JP2011515401A (ja) | 2008-03-20 | 2011-05-19 | アムジエン・インコーポレーテツド | オーロラキナーゼモジュレーターおよび使用方法 |
| WO2010019473A1 (en) | 2008-08-14 | 2010-02-18 | Amgen Inc. | Aurora kinase modulators and methods of use |
| CN105541807B (zh) * | 2015-12-03 | 2018-04-24 | 中国人民解放军南京军区南京总医院 | 一种新型喹唑啉衍生物lu1506及其制备方法和应用 |
| CN105503835B (zh) * | 2015-12-03 | 2018-04-24 | 中国人民解放军南京军区南京总医院 | 一种新型喹唑啉衍生物lu1510及其制备方法和应用 |
| CN105399733B (zh) * | 2015-12-03 | 2018-04-24 | 中国人民解放军南京军区南京总医院 | 一种新型喹唑啉衍生物lu1504及其制备方法和应用 |
| CN105503836B (zh) * | 2015-12-03 | 2018-04-24 | 中国人民解放军南京军区南京总医院 | 一种新型喹唑啉衍生物lu1502及其制备方法和应用 |
| CN106366020B (zh) * | 2016-08-31 | 2018-12-11 | 京博农化科技股份有限公司 | 一种合成手性稻瘟酰胺的方法 |
| CA3112043A1 (en) | 2018-09-10 | 2020-03-19 | Mirati Therapeutics, Inc. | Combination therapies |
Family Cites Families (40)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS5538325A (en) * | 1978-09-11 | 1980-03-17 | Sankyo Co Ltd | 4-anilinoquinazoline derivative and its preparation |
| US4335127A (en) * | 1979-01-08 | 1982-06-15 | Janssen Pharmaceutica, N.V. | Piperidinylalkyl quinazoline compounds, composition and method of use |
| GB2160201B (en) * | 1984-06-14 | 1988-05-11 | Wyeth John & Brother Ltd | Quinazoline and cinnoline derivatives |
| US4921863A (en) * | 1988-02-17 | 1990-05-01 | Eisai Co., Ltd. | Cyclic amine derivatives |
| CA1340821C (en) * | 1988-10-06 | 1999-11-16 | Nobuyuki Fukazawa | Heterocyclic compounds and anticancer-drug reinforcing agents containing them as effective components |
| US5721237A (en) * | 1991-05-10 | 1998-02-24 | Rhone-Poulenc Rorer Pharmaceuticals Inc. | Protein tyrosine kinase aryl and heteroaryl quinazoline compounds having selective inhibition of HER-2 autophosphorylation properties |
| GB9510757D0 (en) * | 1994-09-19 | 1995-07-19 | Wellcome Found | Therapeuticaly active compounds |
| US5747498A (en) * | 1996-05-28 | 1998-05-05 | Pfizer Inc. | Alkynyl and azido-substituted 4-anilinoquinazolines |
| US6046206A (en) * | 1995-06-07 | 2000-04-04 | Cell Pathways, Inc. | Method of treating a patient having a precancerous lesions with amide quinazoline derivatives |
| GB9514265D0 (en) * | 1995-07-13 | 1995-09-13 | Wellcome Found | Hetrocyclic compounds |
| GB9624482D0 (en) * | 1995-12-18 | 1997-01-15 | Zeneca Phaema S A | Chemical compounds |
| US6117433A (en) * | 1996-01-31 | 2000-09-12 | Dsm N.V. | Use of compositions comprising stabilized biologically effective compounds |
| US6004967A (en) * | 1996-09-13 | 1999-12-21 | Sugen, Inc. | Psoriasis treatment with quinazoline compounds |
| US5929080A (en) * | 1997-05-06 | 1999-07-27 | American Cyanamid Company | Method of treating polycystic kidney disease |
| US6384223B1 (en) * | 1998-07-30 | 2002-05-07 | American Home Products Corporation | Substituted quinazoline derivatives |
| US6297258B1 (en) * | 1998-09-29 | 2001-10-02 | American Cyanamid Company | Substituted 3-cyanoquinolines |
| UA71945C2 (en) * | 1999-01-27 | 2005-01-17 | Pfizer Prod Inc | Substituted bicyclic derivatives being used as anticancer agents |
| IL144143A0 (en) * | 1999-02-27 | 2002-05-23 | Boehringer Ingelheim Pharma | 4-amino-quinazoline and quinoline derivatives having an inhibitory effect on signal transduction mediated by tyrosine kinases |
| US6080747A (en) * | 1999-03-05 | 2000-06-27 | Hughes Institute | JAK-3 inhibitors for treating allergic disorders |
| UA73993C2 (uk) * | 2000-06-06 | 2005-10-17 | Астразенека Аб | Хіназолінові похідні для лікування пухлин та фармацевтична композиція |
| US20020082270A1 (en) * | 2000-08-26 | 2002-06-27 | Frank Himmelsbach | Aminoquinazolines which inhibit signal transduction mediated by tyrosine kinases |
| US6562319B2 (en) * | 2001-03-12 | 2003-05-13 | Yissum Research Development Company Of The Hebrew University Of Jerusalem | Radiolabeled irreversible inhibitors of epidermal growth factor receptor tyrosine kinase and their use in radioimaging and radiotherapy |
| WO2002094790A1 (en) * | 2001-05-23 | 2002-11-28 | Mitsubishi Pharma Corporation | Fused heterocyclic compound and medicinal use thereof |
| GB0126433D0 (en) * | 2001-11-03 | 2002-01-02 | Astrazeneca Ab | Compounds |
| DE60231230D1 (de) * | 2001-11-03 | 2009-04-02 | Astrazeneca Ab | Quinazolin derivate als antitumor-mittel |
| TW200813014A (en) * | 2002-03-28 | 2008-03-16 | Astrazeneca Ab | Quinazoline derivatives |
| US6924285B2 (en) * | 2002-03-30 | 2005-08-02 | Boehringer Ingelheim Pharma Gmbh & Co. | Bicyclic heterocyclic compounds, pharmaceutical compositions containing these compounds, their use and process for preparing them |
| GB0309009D0 (en) * | 2003-04-22 | 2003-05-28 | Astrazeneca Ab | Quinazoline derivatives |
| GB0309850D0 (en) * | 2003-04-30 | 2003-06-04 | Astrazeneca Ab | Quinazoline derivatives |
| EP1660479A1 (en) * | 2003-07-29 | 2006-05-31 | Astrazeneca AB | Piperidyl-quinazoline derivatives as tyrosine kinase inhibitors |
| GB0317665D0 (en) * | 2003-07-29 | 2003-09-03 | Astrazeneca Ab | Qinazoline derivatives |
| KR20070027487A (ko) * | 2003-09-16 | 2007-03-09 | 아스트라제네카 아베 | 퀴나졸린 유도체 |
| EP1664028A1 (en) * | 2003-09-16 | 2006-06-07 | AstraZeneca AB | Quinazoline derivatives as tyrosine kinase inhibitors |
| BRPI0414489A8 (pt) * | 2003-09-16 | 2019-01-15 | Astrazeneca Ab | derivado de quinazolina, composição farmacêutica, uso de um derivado de quinazolina, e, processo para a preparação de um derivado de quinazolina |
| GB0321648D0 (en) * | 2003-09-16 | 2003-10-15 | Astrazeneca Ab | Quinazoline derivatives |
| ATE353888T1 (de) * | 2003-09-19 | 2007-03-15 | Astrazeneca Ab | Chinazolinderivate |
| CA2540008A1 (en) * | 2003-09-25 | 2005-04-07 | Astrazeneca Ab | Quinazoline derivatives |
| GB0322409D0 (en) * | 2003-09-25 | 2003-10-29 | Astrazeneca Ab | Quinazoline derivatives |
| GB0326459D0 (en) * | 2003-11-13 | 2003-12-17 | Astrazeneca Ab | Quinazoline derivatives |
| WO2005075439A1 (en) * | 2004-02-03 | 2005-08-18 | Astrazeneca Ab | Quinazoline derivatives |
-
2005
- 2005-06-02 CN CNA200580025966XA patent/CN1993349A/zh active Pending
- 2005-06-02 AU AU2005250224A patent/AU2005250224A1/en not_active Abandoned
- 2005-06-02 MX MXPA06014125A patent/MXPA06014125A/es not_active Application Discontinuation
- 2005-06-02 KR KR1020077000221A patent/KR20070038500A/ko not_active Withdrawn
- 2005-06-02 EP EP05747243A patent/EP1756088A1/en not_active Withdrawn
- 2005-06-02 CA CA002567832A patent/CA2567832A1/en not_active Abandoned
- 2005-06-02 BR BRPI0511741-0A patent/BRPI0511741A/pt not_active IP Right Cessation
- 2005-06-02 WO PCT/GB2005/002215 patent/WO2005118572A1/en not_active Ceased
- 2005-06-02 JP JP2007514135A patent/JP2008501675A/ja active Pending
- 2005-06-02 US US11/628,011 patent/US20070232607A1/en not_active Abandoned
- 2005-06-03 TW TW094118285A patent/TW200602328A/zh unknown
- 2005-06-03 UY UY28940A patent/UY28940A1/es not_active Application Discontinuation
- 2005-06-06 AR ARP050102306A patent/AR049294A1/es unknown
-
2006
- 2006-11-06 IL IL179081A patent/IL179081A0/en unknown
- 2006-11-13 ZA ZA200609427A patent/ZA200609427B/xx unknown
- 2006-12-29 NO NO20066081A patent/NO20066081L/no not_active Application Discontinuation
Also Published As
| Publication number | Publication date |
|---|---|
| CA2567832A1 (en) | 2005-12-15 |
| UY28940A1 (es) | 2006-01-31 |
| EP1756088A1 (en) | 2007-02-28 |
| AU2005250224A1 (en) | 2005-12-15 |
| JP2008501675A (ja) | 2008-01-24 |
| ZA200609427B (en) | 2008-08-27 |
| WO2005118572A1 (en) | 2005-12-15 |
| US20070232607A1 (en) | 2007-10-04 |
| NO20066081L (no) | 2007-02-20 |
| KR20070038500A (ko) | 2007-04-10 |
| BRPI0511741A (pt) | 2008-01-02 |
| MXPA06014125A (es) | 2007-01-31 |
| CN1993349A (zh) | 2007-07-04 |
| IL179081A0 (en) | 2007-03-08 |
| TW200602328A (en) | 2006-01-16 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR049294A1 (es) | DERIVADOS DE QUINAZOLINA; INHIBIDORES DE LA TIROSINA QUINASA DEL RECEPTOR ERBB2; COMPOSICIONES FARMACÉUTICAS QUE LOS CONTIENEN; MÉTODOS PARA SU PREPARACIoN Y SU USO COMO MEDICAMENTO PARA EL TRATAMIENTO O PREVENCIoN DE TUMORES SoLIDOS. | |
| AR045762A1 (es) | Derivados de quinazolina | |
| AR039203A1 (es) | Derivados de quinazolina | |
| PE20060531A1 (es) | Derivados de piridazin-3-(2h)-ona como inhibidores de la fosfodiesterasa 4 | |
| AR061873A1 (es) | Derivados de pirrolotriazina inhibidores de tirosinquinasas, composiciones farmaceuticas que los contienen utiles para el tratamiento de enfermedades proliferativas. | |
| AR046308A1 (es) | Derivados amida | |
| AR033560A1 (es) | Derivados de quinazolina, proceso para su preparacion, composicion farmaceutica, y su uso en la fabricacion de un medicamento, | |
| AR045752A1 (es) | Derivados de quinazolina que poseen actividad antitumoral | |
| AR083339A1 (es) | Compuestos de quinazolina como bloqueadores de los canales de sodio | |
| AR025735A1 (es) | Compuestos terapeuticos | |
| AR047703A1 (es) | Derivados de quinazolina | |
| TW200718686A (en) | Pharmaceutical compounds | |
| PE20040937A1 (es) | Derivados de piridazin-3(2h)-ona como inhibidores de fosfodiesterasa-4 (pde 4) | |
| CO6220949A2 (es) | Derivados pirazolicos como inhibidores de la 11 beta -hsd1 | |
| AR038000A1 (es) | Compuesto derivado de tien[2,3-d]pirimidin-2,4(1h,3h)-diona, composicion farmaceutica, proceso para su preparacion y su uso en la fabricacion de un medicamento | |
| CO6251260A2 (es) | Derivados de bifenilo conformacionalmente restringido para uso como inhibidores del virus de la hepatitis c. | |
| TW200734322A (en) | Indole derivatives exhibiting PGD2 receptor antagonism | |
| AR039399A1 (es) | Compuestos quimicos con actividad doble, procedimientos para su preparacion y composiciones farmaceuticas | |
| AR077849A2 (es) | Compuestos y composiciones como inhibidores de proteina quinasa | |
| AR060050A1 (es) | Compuestos moduladores del receptor de s1p y uso de los mismos | |
| CO5580774A2 (es) | Derivados de quinazolina como agentes antineoplasicos | |
| AR041189A1 (es) | Piridinas y pirimidinas condensadas con actividad anti-angiogenica, que actuan sobre el receptor de tirosina quinasa | |
| TW200800938A (en) | Indole carboxylic acid derivatives exhibiting PGD2 receptor antagonism | |
| PE20081492A1 (es) | Derivados de sulfonamida heterociclicos como antagonista de edg-1 | |
| MX2010000658A (es) | Derivados de pirimidina 934. |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FB | Suspension of granting procedure |